Mutant p53 in cancer: new functions and therapeutic opportunities

PAJ Muller, KH Vousden - Cancer cell, 2014 - cell.com
Many different types of cancer show a high incidence of TP53 mutations, leading to the
expression of mutant p53 proteins. There is growing evidence that these mutant p53s have …

GOF mutant p53 in cancers: A therapeutic challenge

L Dolma, PAJ Muller - Cancers, 2022 - mdpi.com
Simple Summary In normal cells, p53 is a protein which regulates the cell cycle progression
to ensure normal cell division, growth, and development. However, in cancer, changes in the …

Flower isoforms promote competitive growth in cancer

E Madan, CJ Pelham, M Nagane, TM Parker… - Nature, 2019 - nature.com
In humans, the adaptive immune system uses the exchange of information between cells to
detect and eliminate foreign or damaged cells; however, the removal of unwanted cells does …

HIF-transcribed p53 chaperones HIF-1α

E Madan, TM Parker, CJ Pelham… - Nucleic acids …, 2019 - academic.oup.com
Chronic hypoxia is associated with a variety of physiological conditions such as rheumatoid
arthritis, ischemia/reperfusion injury, stroke, diabetic vasculopathy, epilepsy and cancer. At …

[HTML][HTML] Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses

J Obacz, S Pastorekova, B Vojtesek, R Hrstka - Molecular cancer, 2013 - Springer
Abnormal rates of growth together with metastatic potential and lack of susceptibility to
cellular signals leading to apoptosis are widely investigated characteristics of tumors that …

Mutant p53 oncogenicity: dominant-negative or gain-of-function?

Y Stein, R Aloni-Grinstein, V Rotter - Carcinogenesis, 2020 - academic.oup.com
The p53 protein is mutated in about 50% of human cancers. Aside from losing its tumor-
suppressive activities, mutant p53 may acquire pro-oncogenic activity, which is facilitated by …

The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2)

H Hu, S Li, X Cui, X Lv, Y Jiao, F Yu, H Yao… - Journal of Biological …, 2013 - ASBMB
MicroRNAs are involved in regulating the biology of cancer cells, but their involvement in
chemoresistance is not fully understood. We found that miR-663 was up-regulated in our …

Anticancer therapeutic strategies targeting p53 aggregation

GDS Ferretti, J Quarti, G Dos Santos… - International Journal of …, 2022 - mdpi.com
p53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When
mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater …

[HTML][HTML] Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer

Y Ciani, T Fedrizzi, D Prandi, F Lorenzin, A Locallo… - Cell Systems, 2022 - cell.com
Pan-cancer studies sketched the genomic landscape of the tumor types spectrum. We
delineated the purity-and ploidy-adjusted allele-specific profiles of 4,950 patients across 27 …

The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53

E Madan, TM Parker, MR Bauer, A Dhiman… - Journal of Biological …, 2018 - ASBMB
p53 is an important tumor-suppressor protein that is mutated in more than 50% of cancers.
Strategies for restoring normal p53 function are complicated by the oncogenic properties of …